Date: 2012-10-24
Type of information: Grant
Company: Orizon (Spain)
Investors: Ministry of Economy and Competitiveness (Spain)
Amount: € 1.1 million
Funding type: grant
Planned used: The grant will be used to fund the development and characterization of Oryzon’s LSD1 inhibitors in hematological malignancies with a particular focus in acute myeloid leukemia.
Others: Orizon, a privately held biotechnology company, has announced that it was awarded a 36 month 1.103.602 Euros grant under the INNPACTO-2012 Collaborative Program from the Ministry of Economy and Competitiveness
of the Spanish Government. A substantial part of the grant will be devoted to finance the clinical phase 1
studies in acute leukemia of Oryzon’s LSD1 inhibitor that is nearing the end of preclinical development. Clinical activities in Spain will be developed by the hospital Valle de Hebron in Barcelona
Oryzon is the leader of this collaborative program that involves other Spanish companies and Institutions working on hematological malignancies. The consortium has been funded with 2.775.683 Euros.
The Hospital Valle de Hebron in Barcelona will develop the clinical activities in Spain. The company also has an agreement with CANCER RESEARCH UK’S Paterson Institute for Cancer Research that contemplates the possibility that The Christie NHS Foundation Trust - a specialist cancer hospital serving the North West of England - be chosen to perform part of the Phase I/IIA studies planned for next year.
Therapeutic area: Cancer - Oncology
